Background {#Sec1}
==========

The magnitude of safety risks related to medications of the older adults has been evidenced by numerous studies \[[@CR1], [@CR2]\], but less is known of how to manage and prevent these risks in different health care settings. Since the 1990s, both explicit and implicit criteria have been established to decrease prescribing of potentially inappropriate medicines (PIMs) for the older adults \[[@CR3]--[@CR5]\]. These criteria are useless unless they are implemented routinely throughout health care. Recently, the implementation has been facilitated through electronic databases, software applications and clinical decision support systems (CDSS), which have dramatically evolved over the last decade \[[@CR6], [@CR7]\]. The databases and CDSS systems can prospectively detect PIMs and other medication safety risks, but qualified healthcare professionals are needed to make the final decision using clinical judgement based on comprehensive patient information. Efficient use of these modern tools and skill-sets requires coordinated medication management processes in different healthcare settings.

Finland is one of the countries with advanced national health portals, databases and prospective screening systems for managing drug-related risks (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR8]--[@CR11]\]. Within less than 20 years, a wide range of medication risk management tools have been developed, with the Finnish Medical Society Duodecim playing a major role in their development \[[@CR9]\]. These tools are widely available in Finnish health care, including community pharmacies.Fig. 1Medication risk management tools and databases launched in Finland since 2004 and currently widely available in health care and community pharmacies

Even though these innovative prospective medication risk management tools and databases are widely available in Finland, they do not form an integrated medication management process. Health care providers and units work independently, without coordination, and no one seems to have clear responsibility for identifying and solving individual patients' drug-related problems (DRPs) \[[@CR12]\].

The aim of this study was to integrate risk assessment tools, procedures and databases available in Finland to form a coordinated medication management model (CoMM) involving home care nurses and practical nurses (PNs), physicians and community pharmacists in the medication process of older home care clients. A study design was also developed for assessing the effectiveness of CoMM.

Methods/Design {#Sec2}
==============

Context of the study and its importance for ongoing social and health services reform in Finland {#Sec3}
------------------------------------------------------------------------------------------------

Health care services in Finland are primarily funded and organized by municipalities \[[@CR13]\]. The services are divided into primary care and specialized care services. The municipalities and individual residents may acquire services from the public and private health care providers or the third sector. Medicine supply and related pharmaceutical services for outpatients are provided by private community pharmacies. Currently, the Finnish health care system is undergoing a massive reform \[[@CR14]\]. The goal is to improve integration between primary and specialized care and integrate social and health services from the clients' perspective. Integration concerns service provision and funding as they both are currently fragmented.

Long-term home care services for the older adults are a critically important part of health care delivery in Finland as in many other countries \[[@CR15], [@CR16]\]. Currently they are mostly based on regular, even daily, encounters with home care PNs, coordinated by home care nurses. The allocation of physicians' time for clients is limited and will become even more limited in the future as the proportion of the older adults is increasing \[[@CR17]\]. This is putting more pressure on developing new collaborative procedures for monitoring benefits and risks of medication therapies. As part of reorganizing the care PNsʼ involvement in monitoring medication risks and benefits could be enhanced, but PNs have the very basics of relevant pharmacotherapy \[[@CR18]\]. A need for enhancing pharmacists' involvement in medication management of the older adults is identified \[[@CR12], [@CR19]\].

The aim of this study was to coordinate resources for prospective medication risk management of home care clients ≥ 65 years in primary care and to develop a study design for demonstrating effectiveness of the procedure.

Study setting: participating organizations, health professionals and home care clients {#Sec4}
--------------------------------------------------------------------------------------

This study is conducted within publicly funded primary care in Lohja, a municipality in Southern Finland with 47,000 inhabitants. Health care units involved in the study are: Lohja Home Care Unit, Lohja Health Center, and a private community pharmacy (Lohja 1st Pharmacy). A clinically trained researcher (TT) from the research group coordinated the development of CoMM and the design for the effectiveness study in close cooperation with the health care providers involved in home care in Lohja.

Lohja Home Care Unit is divided into five service areas, each having a leading nurse, nurses and PNs who mostly conduct home visits. Nurses consult physicians (working in the Lohja Health Center) as needed, but the physicians meet the patients infrequently. Community pharmacists from the Lohja 1st Pharmacy had primarily a standard BSc(Pharm) or MSc(Pharm) degree with long-term in-house training for geriatric pharmacotherapy and managing DRPs in the older adults, but a pharmacist with accreditation in comprehensive medication reviews (CMRs) \[[@CR20]\] was available as needed. All these pharmacists are termed "pharmacists" in this report.

### Participants {#Sec5}

Home care clients were recruited in the study by nurses and PNs. They individually approached their clients and/or their closest proxy and invited them to participate in the study. Announcements in the local newspaper were also used. The recruitment process was carried out between September 2015 and December 2015. The inclusion criteria were: 1) ≥ 65 years old, home-dwelling resident; 2) receives regular home care from the city of Lohja; 3) uses at least one medicine; 4) voluntary participation, written informed consent to participate in the study given by participant or closest proxy.

Study design {#Sec6}
------------

This study applied action research method to develop the CoMM. Action research method is increasingly being used in health services research \[[@CR21], [@CR22]\]. When applying this method, the researcher works explicitly with and for people rather than undertaking research on them \[[@CR22]\]. The model development was theoretically guided by Reason's systems-based risk management theory on preventing human errors \[[@CR23]\], complemented by Hepler and Strand's basic principles of identifying, solving and preventing DRPs \[[@CR24]\]. Clyne's model was applied for categorization of comprehensiveness of medication reviews \[[@CR25]\].

### Development process of CoMM (intervention) and study design for demonstrating its effectiveness {#Sec7}

The goal was to construct a collaborative procedure which utilizes each profession's resources in a rational way. The coordination of the use of the risk management tools and resources illustrated in Fig. [1](#Fig1){ref-type="fig"} was part of the process.

The development process encompassed four main steps (Fig. [2](#Fig2){ref-type="fig"}). During each step, the coordinating pharmacist/researcher (TT) worked closely with the home care nurses and PNs, their manager (nurse), physicians involved in home care and the community pharmacists.Fig. 2Development process of coordinated medication management model (CoMM) using action research method (modified from Lewin 1946 \[[@CR21]\], Meyer 2000 \[[@CR22]\])

Exploration step (I) included orientation to each organization's current medication management practices targeted to older home care clients. It also covered identification of medication management tools and procedures applied locally in Lohja compared to those generally available in Finland (Fig. [1](#Fig1){ref-type="fig"}). Actual tasks and responsibilities for each professional were defined in regular joint meetings with the coordinating pharmacist (TT), the pharmacy owner (ES) and the responsible nurse of home care service area (KP).

An inventory of clinical measures, used in routine clinical practice in Lohja Home Care, was conducted to include them as outcome measures in the effectiveness study design protocol. The ECHO model, which covers economic, clinical and humanistic outcomes, was applied for their selection and categorization \[[@CR26]\]. Systematic review of Kiiski et al. (2016) \[[@CR27]\], and other previous literature were applied to learn about experiences of rigorous study designs for assessing effectiveness of collaborative medication management models for the older home care clients.

Installation step (II) was to prepare the participating organizations for the CoMM. Home care nurses, PNs, physicians and pharmacists were informed prior to the study and encouraged continuously to comment on the model construction. Personnel training sessions needed to support the model construction were jointly planned with the researchers and home care management. The coordinating pharmacist organized trainings for PNs related to the recruitment process, medication reconciliation \[[@CR28]\] and use of clinical tests. PNs were also trained on the content and use of the Drug-Related Problem Risk Assessment Tool (DRP-RAT) \[[@CR8], [@CR29]\] and about Lohja Home Care Unit's principles in medication management \[[@CR30]\].

Finishing the CoMM (III) aimed to decide the way to solve the identified clinically significant DRPs and allocate medication reviews according to the severity of the DRPs. In the consensus meeting home care physicians, home care managers, leading nurses, community pharmacists, coordinating pharmacist and the research group discussed to agree on tasks and to set up criteria for medication reviews and their comprehensiveness. Steps and procedures related to patient information transfer, interprofessional collaboration and adequate follow-ups were discussed.

After finishing the development of CoMM, its full operation started (IV). The coordinating pharmacist worked closely with the home care practitioners and community pharmacists, facilitating integration between stages and tasks of the health care providers involved. This enabled reflection of the model's feasibility.

Study design for assessing effectiveness of CoMM was developed and selection of outcome measures was made in collaboration with Lohja Home Care and the research group utilizing published evidence on assessing effectiveness of medication review procedures. Selection was made considering study purposes, reliability, validity, sensitivity and specificity of measures and feasibility of carrying out the measurements in clinical practice. Measures already in use were prioritized to minimize additional work for nurses and PNs and inconvenience for the patients.

Description of developed CoMM for home care clients (intervention) {#Sec8}
------------------------------------------------------------------

The developed CoMM consists of five main stages in which clinically significant DRPs can be identified and solved using collaborative procedures and medication reviews (Fig. [3](#Fig3){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). PNs were trained to observe potential medication risks on routine home visits more systematically than before and to report detected clinically significant DRPs to the coordinating pharmacist (Fig. [3](#Fig3){ref-type="fig"}: Stage I: Risk Assessment). The coordinating pharmacist prepared the cases for the triage meeting (Fig. [3](#Fig3){ref-type="fig"}: Stages I and II), in which the leading home care physician and the coordinating pharmacist decided on further actions for clients with clinically significant DRPs (50--70 cases per triage meeting of two hours). The actions included more comprehensive medication reviews according to the needs of the clients involving their own physicians and nurses/PNs. In most complicated cases also home visit and the client's clinical interview were conducted (Fig. [3](#Fig3){ref-type="fig"}: Stage III). Based on the information gathered in Stages I-III client's personal physician made decisions on required actions (Fig. [3](#Fig3){ref-type="fig"}: Stage IV) and follow-up was organized (Fig. [3](#Fig3){ref-type="fig"}: Stage V).Fig. 3Developed coordinated medication management model (CoMM) for older home care clientsTable 1Agreed tasks of each healthcare professional and tools used in the coordinated medication management model (CoMM)Healthcare professionalsTasks in the coordinated medication management modelTools usedHome care nurses (practical nurses, nurses)Medication reconciliation\
Medication risk assessments\
Clinical tests to assess clients' functioning and disability (at baseline, 12 and 24 month follow-up)Medication lists, usual home visits\
Clinical interviews with the DRP-RAT\
a) Measures used in usual clinical practice: functional ability (RAVA) \[[@CR37]\], physical performance (The five-times-sit-to-stand test) \[[@CR38], [@CR39]\], cognitive functioning (MMSE) \[[@CR40]\], depression (GDS-15) \[[@CR41]\] and malnutrition (MNA) \[[@CR42]\].\
b) Added measures: difficulties related to urination (UDI-6) \[[@CR43]\], orthostatic hypotension (3 min test) \[[@CR44]\] and alcohol use (AUDIT-C) \[[@CR45]\].Implementing medication changes and monitoring their outcomesRegular home visits as usual\
Informing physicians when neededCommunity pharmacistsPrescription review (PR)Clinically significant drug-drug interactions (DDIs) (SFINX) \[[@CR32]\]\
Potentially inappropriate medicines (PIMs) according to Beers 2015 criteria \[[@CR46]\], anticholinergic and serotonergic loads of medicines (Salko) \[[@CR33]\].Medication review (MR)Patient information: medication list, DRP-RAT and glomerulus filtration rate (GFR) results\
Other tools used: SFINX (DDIs), Pharao (Cumulative scoring of the anticholinergicity, bleeding risk, constipation, orthostatic hypotension, prolongation of QT interval, nephrotoxicity, sedation, convulsion risk and serotonergicity of the patient's medication) \[[@CR47]\], Salko (PIMs) \[[@CR33]\], Renbase (Renal function and appropriateness of doses/medicines used) \[[@CR9]\].Comprehensive medication review (CMR) conducted by a qualified pharmacist (TT, SL)Patient information: medication list, DRP-RAT and GFR results, diagnosis, laboratory test results.\
Tools used: As in MR, complemented by client's clinical interview \[[@CR20], [@CR48]\]Coordinating pharmacistTrainings of the PNs for the recruitment process, CoMM and use of DRP-RAT (MD)Meetings, discussions, personal guidance, DRP-RAT training \[[@CR29]\]Coordinating and organizing processes for CoMMConstructing the CoMM structure through observations, meetings, contacts and negotiations with organizations, health care professionals, researchers and home care clients involved, organizing processes and interactive training, providing training, guidance and feedback, reflecting the literature and guidelines on geriatric care and pharmacotherapyPreparing triage meetings with the leading home care physician to decide on actions for clients with clinically significant DRPsPrescription review findings (from SFINX and Salko databases) and DRP-RAT results.Leading home care physicianTriage meetings with the coordinating pharmacist to decide on actions for clients with clinically significant DRPs (50--70 cases per triage meeting of 2 h)Prescription review findings (from SFINX and Salko databases) and DRP-RAT results.Client's personal physicianCase-conferences with pharmacists concerning clients with clinically significant DRPs identified in MR and CMR.\
Decisions on the medication changes and how they will be implemented.Medication lists accomplished with the SFINX and Salko data, DRP-RAT results, results from the clinical tests, laboratory test (GFR), MR and CMR report, including client's clinical interview.*Abbreviations*: *DRP-RAT* Drug-Related Problem Risk Assessment Tool \[[@CR31]\], *MMSE* Mini Mental State Examination \[[@CR40]\], *GDS-15* Geriatric Depression Scale \[[@CR41]\], *MNA* The Mini Nutritional Assessment \[[@CR42]\], *UDI-6* Urinary Distress Inventory \[[@CR43]\], *AUDIT-C* Alcohol Use Disorder Identification Test, version C \[[@CR45]\], *SFINX* Drug-drug interaction database's new name since March 2017 is INXBASE, *Pharao* adverse effects database's new name since March 2017 is RISKBASE

Collaborative tasks of each healthcare professional in the developed model (Fig. [3](#Fig3){ref-type="fig"}) are described in Table [1](#Tab1){ref-type="table"}. Nurses and PNs had a key role in clinical follow-up and identifying clients with clinically significant DRPs through gathering and bringing information about clients' symptoms and signs by DRP-RAT. Community pharmacists' pharmacotherapeutic skills were utilized in medication reviews at Stage III (Fig. [3](#Fig3){ref-type="fig"}). Physicians' resources were allocated for clinical decision making at the triage stage (Stage II) and for deciding on actions for clients with complicated DRPs analyzed more in detail in prescription review (PR), medication review (MR) or comprehensive medication review (CMR). (Stage IV). The coordinating pharmacist had a key role in organizing and coordinating medication management processes between the fragmented organizations involving different health care providers, and in preparing and participating in the triage meetings followed by different level medication reviews.

Description of study design for assessment of CoMM's outcomes and effectiveness {#Sec9}
-------------------------------------------------------------------------------

Randomized controlled trial (RCT) was selected for assessing the effectiveness of CoMM.

### Trial design {#Sec10}

The CoMM study is a randomized controlled superiority trial with two parallel groups, a 1:1 randomization (intervention and control).

### Randomization {#Sec11}

Participants were randomized to an intervention group (IG) and a control group (CG) receiving standard home care. To prevent contamination between IG and CG and subsequent dilution of the intervention, participants were randomized by home care areas (2 areas to the IG, 3 areas to the CG) since each home care area has its own nursing staff. The randomization was performed by sealed envelopes. The study is considered as open-label. The IG (*n* = 104) received the intervention (CoMM) during the first year, while the CG (*n* = 87) received standard care and received the same intervention after the first year (delayed intervention as control).

### Participant timeline {#Sec12}

Selected study period was 2 years with measurements at baseline (in 2015), and at 12 (in 2016) and 24 months (in the end of year 2017).

### Sample size {#Sec13}

The study sample was all home care clients, meeting inclusion criteria and giving voluntary informed consent, in the Lohja Home Care Unit due to the practical, administrative and financial issues. Sample size calculations were not performed.

### Outcome measures {#Sec14}

Selected primary outcome measures assess appropriateness of the medications used, general health status and functional ability of the older adults, but also target to specific symptoms that can be potentially caused as adverse effects of medications (Table [1](#Tab1){ref-type="table"}). Majority of selected clinical measures were used in usual clinical practice in Lohja Home Care. Medication-specific measures include assessment of clinically significant DRPs by using DRP-RAT \[[@CR31]\] and electronic screening tools (SFINX, Salko) for identifying PIMs for the older adults, anticholinergic and serotonergic load and clinically significant drug-drug interactions (DDIs) \[[@CR32], [@CR33]\]. Medicines will be classified according to the anatomical therapeutic chemical (ATC) classification system \[[@CR34]\]. Use of health services will be measured as visits to physicians, frequency of visits of home care personnel and frequency of hospital days and will be used as a secondary outcome.

### Data collection methods and data management {#Sec15}

Home care nurses and practical nurses conduct clinical tests and DRP-RAT --assessments, compile medication lists and deliver the data to the research coordinator (TT). Pharmacists use case report form in medication reviews and research coordinator receives the data. Data are entered into a computerized database by the research coordinator. All patients will be given a unique study number to preserve confidentiality. The collected data will be verified for accuracy, missing data, and data consistency with the documents source (medication lists, clinical test forms).

### Statistical methods {#Sec16}

Data will be analyzed on an intention to treat principle, including all randomized participants in the group to which they were randomly assigned. Also per protocol analysis to compare participants from intervention group with clinically significant medication changes conducted due to CMR, MR or PR, with control group will be performed.

The effectiveness of intervention compared to controls receiving standard home care will be first analyzed with unadjusted analysis. If there exists any group differences in participant characteristics or clinical outcomes at baseline, these variables will be included in adjusted analysis.

Descriptive statistics (mean, median or percentages as appropriate) will be used to summarize the participant characteristics and clinical outcomes. The comparison in the participant characteristics and clinical outcomes at baseline between groups will be done by two-sample t-test for normally distributed variables and by Mann-Whitney U-test for non-normally distributed variables. Chi-square test will be used for categorical variables.

Continuous outcomes will be analyzed with analysis of variance or covariance and repeated measures analysis of variance or covariance. Dichotomous outcomes will be analyzed by binary logistic regression and ordinal outcomes by cumulative logistic regression using generalized estimating equations to account for the correlation between the repeated measurements. Participants with baseline measurement and at least one follow-up measurement will be included in longitudinal analysis. Two-sided statistical tests with a 5% level of significance will be used.

### Data monitoring {#Sec17}

The research coordinator ensures the successful completion of the study, and the collection of data. She also ensures the compliance with the study protocol, the organization of the follow-up of the study participants and receives information about drop-outs.

### Harms -- End of protocol {#Sec18}

Any harm to the participants will not be expected due to this study. Participating physicians from their own health system decide potential changes to patients' medication according to their normal clinical practice. Participants can withdraw their consent any time.

### Protocol amendments {#Sec19}

Important protocol amendment would require new ethical approval. Any important amendments have not been made during the study.

### Confidentiality {#Sec20}

The personal information of the participants is kept in a separate file. The research coordinator ensures the protection of the confidentiality of the data. Personal information is not entered to the study database, study numbers are used instead.

### Dissemination policy {#Sec21}

The results of the effectiveness study will be published in a peer-reviewed journal. Separate manuscripts may be published on primary and secondary outcomes.

Discussion {#Sec22}
==========

This study produced a 5-stage medication management procedure suitable for screening medications of a high number of home care clients and identifying clients with potential clinically significant DRPs. The model coordinates existing resources to prospective medication risk assessment providing also tools to solve identified DRPs. Nurses and PNs' role in conducting DRP risk assessments, medication reconciliation and clinical tests during their usual home visits was clarified and reinforced. They also had a key role in implementing and following up medication changes. Triage meetings was a new and feasible way for allocating medication reviews according to clinical needs, but using a minimum of physician's time. The coordinating pharmacist prepared triage meetings by summing up each client's DRP risk information from different sources and making preliminary proposals for required actions for physician's consideration. Community pharmacists' contribution changed towards more clinical in the model. They conducted medication reviews and worked closer than before with nurses, PNs and physicians. In future, the coordinating role could be delegated to community pharmacists.

The model contains an adequate follow-up stage to confirm that the agreed medication changes will be actually implemented and the client's health status monitored. This stage is often missing or omitted, but it is crucial for obtaining any benefits from DRP risk assessments and medication reviews \[[@CR27]\].

The model focuses on clinically significant DRPs which may occur due to patient-related factors (e.g., age-related physiological alterations, co-morbidities, poor adherence), pharmacological effects of the medications (particularly adverse drug reactions (ADRs), high-risk medications) or the medication process of the client (e.g., poor medication management, infrequent follow-ups, various health care providers) \[[@CR31]\]. These are the aspects that PNs were trained to observe during home visits by using the DRP-RAT tool as a guide in communication with their client or the proxy. Home visits were primarily conducted by clients' own PNs who knew them. A clinically trained pharmacist conducted home visits only in cases in which risk assessment conducted by a PN indicated serious DRPs needing more detailed investigation. These cases were a minority in our data.

The CoMM development process revealed educational needs both in geriatric pharmacotherapy and understanding system-based medication risk management. These needs were identified in all participating health care professionals and community pharmacists. This kind of model development processes should include interprofessional training that support competence and practice development \[[@CR35]\]. In our process, home care nursing staff and physicians had training on identifying clinically significant DRPs by using DRP-RAT and deprescribing \[[@CR8], [@CR31], [@CR36]\]. Community pharmacists were identified to need training for conducting DRP risk assessments and taking more responsibility of the triage stage in the future. The coordinating pharmacist was a valuable resource in identifying educational needs and educating staff.

Our experience is that health care teams in home care benefit from having a coordinating pharmacist with qualifications in CMRs, geriatric pharmacotherapy and system-based medication risk management. Our study revealed that organizations and health care units involved in home care clients' medication therapy are working independently in silos, nobody takes holistic responsibility for medications. The coordinating pharmacist was needed to facilitate construction of new processes and introduce new tools and approaches in medication management. She scheduled the progression of risk management stages (see Fig. [3](#Fig3){ref-type="fig"}) and regularly highlighted the primary goal of the project to those involved: the purpose being to find a feasible way to manage and prevent clinically significant DRPs of the home care clients, not to conduct scientific research. Practitioners involved were not used to working in such close collaboration, which was crucial for the model. Scarce availability of physicians' resources and partly reluctant attitudes towards the new collaborative way of working complicated the arrangement of case-conferences of MRs and CMRs.

System based risk management perspectives through Reason's Swiss Cheese Model \[[@CR23]\] and Hepler and Strand's model \[[@CR24]\], to identify and prevent DRPs, were useful in guiding model development and constructing a shared understanding of medication safety and prospective medication risk management. Our study indicated that practitioners in Finnish health care are not well acquainted with systems thinking and this needs reinforcement in the future.

The strength in using an action research method \[[@CR21]\] in model development lies in its ability to consider practical challenges and produce solutions, considering existing resources. The method contributed to the step by step construction of the CoMM model and description of the responsibilities of each professional involved in the model, which is missing in many other studies \[[@CR27]\]. Transferring the model to other home care localities is possible, but will require long term effort from a qualified coordinator, committed personnel and managers to reach the mature stage of the collaboration that is necessary for sustainable changes in working patterns.

This study produced a RCT with a combination of outcome measures to assess general health status and functional ability of the older adults, but also targeted to symptoms suggestive of adverse effects of medications. DRP-RAT is used as an outcome measure to evaluate potential decreases in clinically significant DRPs. Medication lists are used to investigate changes in the quality of medications (e.g., use of PIMs). According to previous evidence, a selected study period of 2 years should be long enough to demonstrate potential changes in study participants' health outcomes, use of health services and sustainability of changes made in their medications.

The developed CoMM procedure is feasible for screening and reviewing medications of a high number of older home care clients to identify clients with severe DRPs and provide interventions to solve them utilizing existing primary care resources. The coordinating pharmacist was needed to facilitate the construction of new processes and introduce new tools and approaches in medication management of the older home care clients.
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